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IIEF Domain Scores for ITT and PP Subjects Pre-Procedure
and at 3- and 6-Month Follow-Up
ITT
Pre-Procedure
(n ¼ 30)
3 Months
(n ¼ 27)
6 Months
(n ¼ 27)Clariﬁcation of the Pre- and
Post-Treatment Parameter
for Erectile Dysfunction
Treatment
We read the paper by Rogers et al. (1) with great interest as it may
open up a potential new therapeutic approach for patients experi-
encing erectile dysfunction. However, we would like to have further
clariﬁcations about the data/results from the authors before we fully
appreciate the beneﬁcial role of the procedure.
The International Index of Erectile Function (IIEF) is one of the
standard tools of urologists for the assessment of erectile function
(2). The 15 questions covered 5 domains related to sexual function:
erectile function (EF), orgasmic function, sexual desire, intercourse
satisfaction, and overall satisfaction. Among these, the EF domain
is the main area assessed in studies related to the treatment
response of therapy for erectile dysfunction (2–4). Although the
primary feasibility endpoint of this study was set as an increase
of 4 points in the IIEF-6/IIEF-EF domain, the presentation of
the results appeared less clear. In the Results section, including
Table 3 (1), only IIEF, but not IIEF-6, was mentioned. Moreover,
in Figure 4 (1), only the changes in total IIEF score were shown,
but not the IIEF-6 (EF domain score). Therefore, we were
uncertain whether the 59.3% improvement of >4 points was IIEF
(total) or IIEF-6 (EF domain). Moreover, the usual practice of
presenting the results of treatment for erectile dysfunction is to
provide the pre- and post-treatment IIEF-EF domain scores for
easier reference (3,4). Unfortunately, this essential information
was not shown in the article. The only information that we
could obtain was the pre- and post-treatment total IIEF score
provided in Figure 4 (1). Because the mean improvement in total
IIEF score was only w12 points, we were not certain about the
exact contribution of the EF domain alone. Therefore, we would
greatly appreciate if the authors could provide further clariﬁcation
of the results (pre- and post-treatment IIEF-6/EF score). This
would help readers to better assess the potential role of this novel
therapy.IIEF-6 score 15.1  4.4 20.5  7.7 20.5  7.2
Mean IIEF-6 change from
baseline to follow-up for
paired subjects
5.6  7.1 5.7  6.3
PP
Pre-Procedure
(n ¼ 25)
3 Months
(n ¼ 22)
6 Months
(n ¼ 23)
IIEF-6 score 15.5  4.2 22.4  6.3 21.8  6.5
Mean IIEF-6 change from
baseline to follow-up for
paired subjects
7.1  6.3 6.5  6.5
Values are reported for subjects with available data as mean  SD.
IEFF ¼ International Index of Erectile Function; ITT ¼ intention-to-treat; PP ¼ per-protocol.*Chi-Fai Ng, MD
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2883–93.ReplyWe thank Dr. Ng and colleagues for their query. As stated in the
manuscript, the primary feasibility endpoint of the ZEN trial was
obtained at 3 months and was deﬁned as improvement in erectile
function from pre-procedure of the IIEF-6 score by 4 points
in 50% of subjects. These data are presented in Table 3 in our
original article (1), which is labeled “Primary and Secondary
Endpoints.” The IIEF improvement presented in this table
represents the IIEF-6 score as described in the methods section
(although it is described as “IIEF improvement 4 points”).
Figure 4 in our original paper (1) represents the total IIEF score as
described in the ﬁgure legend. We apologize for any confusion this
may have caused. The table below provides further information not
formally presented in the article as to the raw IIEF-6 scores ob-
tained pre-procedure and in follow-up.
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Chronic Total Occlusion
Revascularization Is Alike
Recently, Valenti et al. (1) reported clinical and angiographic
outcomes after chronic total occlusion (CTO) revascularization
with drug-eluting stents (DESs). In this retrospective analysis, the
investigators demonstrated 77% procedural success with wire-based
CTO crossing strategies and concluded that although treatment
with DESs in this complex lesion subset is associated with favor-
able angiographic patency, CTO percutaneous coronary interven-
tion (PCI) involving subintimal tracking and luminal re-entry
(STAR) techniques was independently predictive of recurrent
occlusion. Speciﬁcally, among a small cohort of 54 patients,
recanalization was accomplished in 50 of them, yet ﬁnal Throm-
bolysis In Myocardial Infarction ﬂow grade 3 was achieved in only
34 patients (63%). At 1 year, a 57% reocclusion rate (31/54
attempts) was demonstrated, but only one-half of the STAR group
underwent angiographic follow-up. Reduced 3-year event-free
survival was also described in comparison with patients treated
with non-STAR techniques.
We believe that these ﬁndings represent misinterpretation in
what is considered subintimal dissection and re-entry CTO PCI
and may therefore be misleading regarding the advantages of the
current CTO PCI technique. First, the STAR technique is tradi-
tionally used as a bail-out maneuver for distal lumen entry through
creation of extensive subintimal dissection planes, often with the
unintended consequence of side branch loss. As exempliﬁed in this
and previous (2) studies, it is an unfavorable method associated
with low procedural and clinical success. Moreover, the long-term
success of this method is dependent on infrequent achievement of
ﬁnal TIMI ﬂow and preservation of distal vessel runoff that are
instead the objectives of more targeted re-entry techniques. For
these reasons, STAR is uncommonly performed at leading CTO
centers and should not be confused with more limited and
contemporary subintimal dissection and re-entry methods. Indeed,
it is likely that the majority of all successful CTO recanalizationprocedures involve guidewire advancement through the subintimal
vessel architecture, further confounding what deﬁnes subintimal
and nonsubintimal CTO PCI (3).
In summary, a predominantly antegrade wire-based strategy of
CTO-PCI is associated with low success rates. The STAR tech-
nique and related outcomes described by Valenti et al. (1) do not
represent more common (and contemporary) CTO PCI methods
that involve targeted guidewire re-entry. The expected adverse
outcome described in the present study should therefore not
discourage the application of more contemporary methods of
luminal re-entry that facilitate procedural success (4). More detailed
clinical outcomes speciﬁc to these methods will be reported from
the ongoing clinical study (NCT01435031).*David E. Kandzari, MD
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occlusions. Cathet Cardiovasc Interv 2012;80:807–13.ReplyWe thank Dr. Kandzari and colleagues for their interest in our
study (1). We do not believe that the STAR technique applied to
coronary vessels may be confused with the other techniques used in
chronic total occlusion (CTO) recanalization. The STAR tech-
nique is a relatively quick and easy technique to gain the distal
lumen of the vessel, but the re-entry into the true lumen of all main
branches may be difﬁcult, and even in these cases, the restoration
of a normal ﬂow is achieved in approximately half of cases (63% in
our study).
As stated in their letter, the STAR technique “is uncommonly
performed at leading CTO centers,” and this was the case at our
